Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Blueprint Medicines Corp
(NQ:
BPMC
)
107.80
+0.80 (+0.74%)
Streaming Delayed Price
Updated: 3:43 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corp
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
June 13, 2021
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...
Via
Benzinga
Exposures
Product Safety
Recap: Blueprint Medicines Q1 Earnings
April 29, 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past...
Via
Benzinga
1 Cancer Stock to Buy and Hold for the Next Decade
April 17, 2021
Blueprint Medicines is setting itself up to become the leader in precision oncology.
Via
The Motley Fool
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.